July 18, 2018
Undiagnosed, untreated or poorly managed mental health conditions can drive some people to substance use. In some cases, substance use can become problematic and can destabilize the lives of users. Some people who share equipment for substance use may become infected with hepatitis C virus (HCV) and HIV. In order to help people begin the process of recovering from problematic substance use and, in some cases, hepatitis C virus -- and to help them remain free of HCV re-infection -- a range of support services is needed.
Doctors at the Vancouver Infectious Disease Centre have been caring for people who use substances and who also have viral infections such as HCV and HIV. In the latest report from the centre, a team of healthcare workers reviewed data collected from 148 people who had been using substances for many years. All participants had received treatment with direct-acting antivirals (DAAs) between June 2015 and May 2017 and had been cured.
At the centre, participants received multidisciplinary care to address the following list of issues compiled by the healthcare workers:
This care was provided before, during and after treatment with DAAs. All participants were substance users.
The average profile of participants upon entering the study was as follows:
Commonly used DAAs during the study were as follows:
After an average of 66 weeks of monitoring, no one became re-infected.
The Vancouver team stated that providing relevant health and social services to patients before, during and after HCV treatment helped to decrease the risk of HCV re-infection.
The study was done in an era when overdoses among people who inject drugs have increased in Vancouver (and other parts of North America). These overdoses are increasingly caused by exposure to fentanyl and its analogues. However, no one in the study experienced a fatal overdose. Thus, it is possible that the multidisciplinary care and services provided by the clinic not only helped to prevent re-infection with HCV but also helped to prevent fatal overdoses.
Alimohammadi A, Thiam A, Holseka J, et al. Recurrent viremia after successful hepatitis C virus therapy with direct-acting antiviral therapy in a cohort of people who use drugs. International Liver Congress, 11-15 April 2018, Paris, France. Poster FRI-405.
[Note from TheBodyPRO: This article was originally published by CATIE in June 2018. We have cross-posted it with their permission.]
|HCV Cure and the Long Road to Recovery|
|After Hepatitis C Cure, Kidney Problems Linked to Cocaine Use|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Before and After Sex Worked as Well as Daily PrEP in Preventing HIV|
|For Transgender Women, PrEP Is Safe to Use With Estradiol as Feminizing Hormone Therapy, Study Says|
|This Week in HIV Research: Another Notch in the "Treatment as Prevention" Belt|
|Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant|
|Anthony Fauci Traces the HIV Research Path to U=U|